BioSpace News Archive

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).

OKYO Pharma Limited announced that it received notification from the Listing Qualifications Department of the Nasdaq Stock Market notifying OKYO that it has regained compliance with the minimum $35 million market value requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550.

Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive tumors and organ fibrosis, announced an oral presentation during the ERS International Congress to be held September 9-13 in Milan, Italy.

Lokavant, the clinical trial intelligence platform company, announces the launch of a study planning solution driven by proprietary historical trial data from more than 2,000 studies involving more than 14,000 investigators, 12,000 healthcare institutions, and real-world data (RWD) sources.

Morphic Therapeutic announced that Marc Schegerin, MD, COO & CFO, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:00 AM ET.

Day Zero Diagnostics Inc., a pioneer in infectious disease diagnostics, has received a Phase I Small Business Innovation Research award from the National Institute of Allergies and Infectious Disease of the National Institutes of Health.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 25th Annual Global Investment Conference, being held from September 11-13, 2023.

Paragon Therapeutics, Inc., a biotechnology company dedicated to discovering and developing best-in-class biologics for a range of diseases with high unmet need, announced the achievement of key milestones by its first spinout company, Apogee Therapeutics.

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.